EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application nifedipine extended-release tablets USP, 30mg, 60mg, and 90mg. Aurobindo Pharma’s nifedipine extended-release tablets USP, 30mg, 60mg, and 90mg, are an AB-rated generic equivalent to the reference listed drug (RLD), ADALAT CC of Alvogen Group Holdings.

Nifedipine extended-release tablets are indicated for the treatment of hypertension.

Nifedipine extended-release tablets has an estimated market size of US $95 million for the twelve months ending May 2021, as per IQVIA.